Mostrando 10 resultados de: 11
Filtros aplicados
Subtipo de publicación
Article(11)
Publisher
Cancer Immunology, Immunotherapy(2)
Frontiers in Oncology(2)
Gerontology(2)
Experimental Gerontology(1)
Frontiers in Pharmacology(1)
Área temáticas
Enfermedades(9)
Farmacología y terapéutica(3)
Fisiología humana(3)
Bioquímica(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Origen
scopus(11)
Association among Terminally Differentiated T Cells, Frailty, and Dependency in a Group of Cuban Centenarians
ArticleAbstract: Introduction: Centenarians are considered a model of successful aging. Cuba exhibits one of the oldePalabras claves:Centenarians, Frailty, Immunosenescence, inflammation, terminally differentiated T cellsAutores:Añe-Kouri A.L., Bicet Y.D.L.C., González A., Lage Davila A., Ledón N., Llanez-Gregorich E., Luaces P.L.o., Pereira K., Ramos M.B., Rodríguez M., Rodríguez Y., Saavedra Hernández D., Silva A., Suárez G.M., Tania Crombet, Vidal A.Fuentes:scopusAssociations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusAugmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusBiomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
ArticleAbstract: Purpose: There are well-known alterations occurring within the immune system with aging. CollectivelPalabras claves:cancer vaccine, Immunosenescence, Immunosenescence markers, Non-small cell lung cancerAutores:Fuentes K.P., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Popa X., Saavedra Hernández D., Tania CrombetFuentes:scopusBiomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly
ArticleAbstract: The changes that occur in the immune system with aging are commonly termed immunosenescence. ImmunosPalabras claves:Biomodulina T, Immunosenescence, naïve T cells, Stem cell-like memory T cells, T cellsAutores:Aznar E., Fuertes S.A., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Saavedra Hernández D., Speiser D.E., Suárez G.M., Tania CrombetFuentes:scopusImmune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
ArticleAbstract: SARS-CoV-2 infection causes a range of clinical presentations and induces changes in both innate andPalabras claves:covid-19, eGFR, inflammation, nimotuzumab, SARS-COV-2, T cellsAutores:Añe-Kouri A.L., Armada J.J., González Y.Z., Gregorich E.M.L., Londres H.D., Luaces P.L.o., Martínez A.H., Medel L., Mena J., Ramos M., Saavedra Hernández D., Sánchez Y.H., Tania Crombet, Troche M.Fuentes:scopusImmunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy
ArticleAbstract: This study aimed to investigate the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 gaPalabras claves:adjuvant therapy, Breast Cancer, cytotoxic antibodies, Ganglioside, NeuGcGM3, VaccineAutores:Curbelo I., Estevez A., Fernandez L.E., Gonzalez Z., Luaces P.L.o., Mazorra Z., Mulens V., Pérez K., Rubio M.C., Tania Crombet, Valdes-Zayas A., Vega A.M.Fuentes:scopusImmunosenescence and gender: A study in healthy Cubans
ArticleAbstract: Background: The progressive decline in the immune function during ageing is termed immunosenescence.Palabras claves:Autores:de Jesús Badía Alvarez T., García Verdecia B., Lage Davila A., Leonard Rupalé I., Luaces P.L.o., Mazorra Z., Saavedra Hernández D., Tania CrombetFuentes:scopusUse of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
ArticleAbstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreaPalabras claves:Autores:Caballero A., Calderón N.A., Cepeda M., Diáz Y., Estevez D., Hidalgo C.J., La O Y., Leon K., Lorenzo G., Luaces P.L.o., Martín Y., Mazorra Z., Oyarzábal J.P.A., Pérez Y., Ramos-Suzarte M., Saavedra Hernández D., Santiago W., Tania Crombet, Valenzuela-Silva C.M., Viñet O.Fuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopus